Aldeyra Therapeutics (STU:137) Total Long-Term Liabilities : €5.71 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Aldeyra Therapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was €5.71 Mil.

Aldeyra Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Aldeyra Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Total Long-Term Liabilities Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

13.08

9.40

13.83

14.09

5.75

Aldeyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Liabilities	Get a 7-Day Free Trial															13.98	9.35	2.49	5.75	5.71

Aldeyra Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Aldeyra Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (STU:137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ALDX:USA 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines